@article{846cc1276ef24b78b58c414e1aa114c6,
title = "Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: A new approach",
abstract = "The Alzheimer's disease (AD) Cognitive Behavior Section (ADAS-Cog) is the most commonly used cognitive test in clinical trials of AD. Recent trials have focused on people earlier in the course of disease; however, there are concerns about using the ADAS-Cog at this crucial stage. Using data from the Alzheimer's disease Neuroimaging Initiative study, we used a range of traditional psychometric tests to evaluate those concerns. This issue of Alzheimer's & Dementia includes two articles that evaluate the ADAS-Cog. These articles report evaluations using two psychometric approaches: traditional methods and new methods. In this review, we provide accompanying background information to this program of research.",
keywords = "ADAS-Cog, ADNI, Alzheimer's disease, Cognition, MCI, Neuropsychology, Psychometric",
author = "Posner, {Holly B.} and Stefan Cano and Carrillo, {Maria C.} and Ola Selnes and Yaakov Stern and Thomas, {Ronald G.} and John Zajicek and Jeremy Hobart",
note = "Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd; AstraZeneca; Bayer HealthCare; BioClinica, Inc; Biogen Idec, Inc; Bristol-Myers SquibbCompany; Eisai, Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development, LLC; Medpace, Inc; Merck & Co, Inc; Meso Scale Diagnostics, LLC; Novartis Pharmaceuticals Corporation; Pfizer, Inc; Servier; Synarc, Inc; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private-sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by National Institutes of Health grants P30 AG010129 and K01 AG030514 . We thank Lisa J. Bain for editorial assistance with this manuscript. Copyright: Copyright 2013 Elsevier B.V., All rights reserved.",
year = "2013",
month = feb,
doi = "10.1016/j.jalz.2012.10.008",
language = "English (US)",
volume = "9",
pages = "S56--S60",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1 SUPPL.",
}